ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1309

Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS

Mara ngeles Puche Larrubia1, M.Lourdes Ladehesa-Pineda1, Pilar Font2, Alejandro Escudero Contreras3, Eduardo Collantes-Estevez2 and Clementina López Medina4, 1Hospital Universitario Reina Sofía, Córdoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 3Hospital Universitario Reina Sofía/IMIBIC/Universidad de Córdoba., Cordoba, Spain, 4Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, Comorbidity, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: a) To evaluate the impact of the number of comorbidities on the outcome measures after two years of follow-up in patients with ankylosing spondylitis (AS) and b) to determine whether the number of comorbidities influences the retention rate to the first anti-TNF alpha.

Methods: Observational and prospective study during 2 years of follow-up that includes a subgroup of 749 patients with AS (REGISPONSER-AS) from the REGISPONSER study (Spanish Rheumatology Spondyloarthritis Registry). The patients were divided into three groups according to the number of comorbidities at baseline (0, 1 or ³2 comorbidities). The Patient Reported Outcomes (PROs) evaluated were the Global VAS, BASDAI, ASDAS, BASFI and the mental and physical components from the SF12 questionnaire. Linear regression models were performed using the PROs as the dependent variable and the three groups of patients according to their comorbidities as the explanatory variable. Since disease duration may influence both the number of comorbidities and the PROs, additional models adjusting for this variable were explored. After that, the impact of the number of comorbidities on PROs over two years of follow-up was evaluated using mixed models for repeated measures (MMRM) adjusting for disease duration. Finally, we compared the retention rate to the first anti-TNF alpha across the three groups of patients using a Kaplan-Meier curve and a Log-rank test.

Results: 749 patients were included (mean age 48.37 ± 12.2 years, of which 75.3% were men). The association between the number of comorbidities and the PROs is shown in Table 1. We found that patients with 2 or more comorbidities showed an increase (b coefficient) in all PROs compared with patients without comorbidities. The impact of the number of comorbidities on the PROs after two years of follow-up is shown in Figure 1. In general, patients with two or more comorbidities showed higher scores during the two years of follow-up in Global VAS, BASDAI, ASDAS, BASFI and worse levels of the physical component from the SF12.
The impact of the number of comorbidities on the retention rate of the first anti-TNF is shown in Figure 2. We found a higher probability of discontinuation of the first anti-TNF in patients with 2 or more comorbidities compared with the other two groups (38.2% vs. 26.6% vs. 25.4% for 2 or more comorbidities, 0 and 1 comorbidity, respectively), although these differences were not significant (Log-rank test: p-value = 0.180).

Conclusion: In patients with AS, the presence of 2 or more comorbidities was associated with poorer scores on the outcome measures after two years of follow-up, in comparison with patients without comorbidities. Despite the three groups showed a similar use of anti-TNF alpha, a greater tendency of discontinuation of the first anti-TNF was observed in patients with 2 or more comorbidities.

Table 1. Association of the number of comorbidities with PROs.

Figure 1. Impact of the number of comorbidities on PROs over two years of follow-up.

Figure 2. Impact of the number of comorbidities on the adherence to the first TNF-alpha blocker.


Disclosures: M. Puche Larrubia, None; M. Ladehesa-Pineda, None; P. Font, None; A. Escudero Contreras, None; E. Collantes-Estevez, None; C. López Medina, None.

To cite this abstract in AMA style:

Puche Larrubia M, Ladehesa-Pineda M, Font P, Escudero Contreras A, Collantes-Estevez E, López Medina C. Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impact-of-the-number-of-comorbidities-on-the-outcome-measures-and-on-the-retention-rate-of-the-first-anti-tnf-in-patients-with-ankylosing-spondylitis-two-year-follow-up-regisponser-as/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-the-number-of-comorbidities-on-the-outcome-measures-and-on-the-retention-rate-of-the-first-anti-tnf-in-patients-with-ankylosing-spondylitis-two-year-follow-up-regisponser-as/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology